SCHEMBL14819035

SCHEMBL14819035

O=S(=O)(O)c1ccc(NNc2ccc(O)cc2O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
CA2 P00918 5/20 0.39
CA1 P00915 4/20 0.39
HSD17B10 Q99714 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 2/20 0.38
EGFR P00533 1/20 0.38
CA5A P35218 1/20 0.38
TIMP3 P35625 1/20 0.38
PRMT1 Q99873 1/20 0.37
HPGD P15428 3/20 0.37
HIF1A Q16665 2/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
THRB P10828 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37
RECQL P46063 1/20 0.37
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8848749 0.78 LMNA (0.56) LMNACA2CA1HSD17B10ALDH1A1
SCHEMBL9813346 0.77 TIMP3 (0.51) LMNAHSD17B10ALDH1A1GAATIMP3
SCHEMBL24418218 0.76 CXCR1 (0.44) LMNACA2CA1HSD17B10ALDH1A1
SCHEMBL14819058 0.76 KMT2A (0.51) LMNAALDH1A1GAAHPGDPOLB
SCHEMBL14819028 0.76 APEX1 (0.53) LMNAHSD17B10ALDH1A1PRMT1HIF1A
SCHEMBL9902951 0.73 SNCA (0.41) LMNAHSD17B10ALDH1A1TIMP3PRMT1
SCHEMBL11320674 0.71 LMNA (0.74) LMNACA2CA1HSD17B10ALDH1A1
SCHEMBL28968591 0.71 TSHR (0.62) LMNACA2CA1ALDH1A1GAA
SCHEMBL17951496 0.71 CA12 (0.51) CA2CA1HSD17B10ALDH1A1GAA
Phenolsulfonic Acid SCHEMBL10622999 0.70 LMNA (1.00) LMNACA2CA1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078186-A1 AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130078186-A1 AZO COMPOUNDS REDUCING FORMATION AND TOXICITY OF AMYLOID BETA AGGREGATION INTERMEDIATES APP, TTR, CRYAB LMNA 1454/4885CA2 1104/4885CA1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.